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                                                  ABSTRACT 
     In nasopharyngeal carcinoma (NPC), Epstein-Barr virus (EBV) infection is mainly 
latent, and the tumor cells contain episomal viral DNA. We have shown that the 
acyclic nucleoside phosphonate analog, cidofovir [(S)-1-[3-hydroxy-2-
(phosphonylmethoxy)-propyl]cytosine] (HPMPC), inhibits growth of NPC xenografts 
in nude mice by causing apoptosis. The ribonucleotide reductase (RR) inhibitors, 
hydroxyurea and didox (3,4-dihydroxybenzohydroxamic acid), have been 
demonstrated to inhibit neoplastic growth and are used as antiviral and anticancer 
agents. Here, we show that RR inhibitors enhance the antitumor effect of cidofovir in 
EBV-transformed epithelial cells. MTT assays indicate that hydroxyurea and didox 
enhance cidofovir-induced cell toxicity in NPC-KT cells, an EBV-positive epithelial 
cell line derived from NPC. The effect is due to enhancement of apoptosis through the 
caspase cascade as shown by pronounced cleavage of poly (ADP-ribose) polymerase. 
Finally, hydroxyurea strikingly enhanced the cidofovir-induced growth-inhibitory 
effect on NPC grown in athymic mice. The results suggest that RR inhibitors should 
enhance the antitumor effect of acyclic nucleoside phosphonate analogs on NPC.  
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                                               INTRODUCTION 
     Cidofovir, [(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl) cytosine] (HPMPC) 
belongs to a new class of antiviral molecules, the acyclic nucleoside phosphonate 
analogs. The activity spectrum of cidofovir encompasses virtually all members of the 
human herpesviruses: herpes simplex virus type 1 and 2, varicella-zoster virus, 
cytomegalovirus, Epstein-Barr virus (EBV) and human herpes viruses 6, 7, and 8, as 
well as polyomavirus, papillomavirus, adenovirus, and poxvirus infections1. This 
class of molecules is characterized by a stable phosphonate linkage between the 
acyclic nucleoside and the phosphate moiety1,2. As a consequence, in contrast to 
antiviral drugs such as acyclovir and ganciclovir, cidofovir bypasses the first 
phosphorylation step by herpesvirus-encoded kinases1,2. Thus, cidofovir is effective 
against thymidine kinase (TK)-deficient HSV and VZV strains and protein kinase-
deficient CMV strains that are resistant to acyclovir and ganciclovir1,2. Cidofovir 
enters the cell by endocytosis3 and is then metabolized to the diphosphorylated form 
by cellular kinases4,5. Diphosphorylated cidofovir acts as both a competitive inhibitor 
and an alternative substrate of dCTP in the viral DNA-polymerase reaction6. Two 
consecutive cidofovir molecules must be incorporated at the 3’ end of the DNA chain 
to effectively terminate DNA polymerization7.       
     Cidofovir also inhibits growth of tumors in which virally encoded DNA 
polymerases are not expressed and therefore through a different mechanism. 
Cidofovir was effective for treatment of extensive HPV-infected squamous 
papillomatous lesions of the hypopharynx and esophagus8. Intratumoral injections of 
cidofovir in patients with recurrent laryngeal papillomatosis produced complete and 
permanent responses9,10.  
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     Ribonucleotide reductases (RR) play a central role in DNA biosynthesis furnishing 
a continuous and balanced supply of the four deoxyribonucleoside triphosphates 
(dNTPs). The reaction catalyzed in mammalian cells represents the rate-limiting step 
of the de novo synthesis pathway of dNTPs and ultimately governs cell proliferation11. 
RR activity also seems to play an important role in DNA repair12. The primary 
mechanism of action of hydroxyurea is through the inhibition of RR. This mechanism 
accounts for the cell-cycle-specificity of hydroxyurea: the drug is active in S phase, 
producing arrest of proliferating cell populations in the G1/S phase of the cell cycle13. 
Hydroxyurea has been demonstrated to inhibit neoplastic growth in vitro and in vivo 
and is used in cancer chemotherapy14.  
     Nasopharyngeal carcinoma (NPC) is universally associated with EBV infection15. 
In NPC, EBV infection is mainly latent, and the tumors contain episomal viral DNA 
rather than linear genomes. Episomal DNA is replicated by host DNA polymerase, 
whereas the linear genomes produced in cytolytic infection are replicated by EBV 
DNA polymerase. Previously, we showed that cidofovir induced rapid cell death 
through apoptosis in EBV-positive NPC grown in athymic nude mice16. Intratumoral 
injection of the related drugs 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) or 9-2-
(R)-(phosphonomethoxy)propyladenine (PMPA) also slowed tumor growth, but only 
moderately17. The effect of the drugs on NPC is independent of EBV replication.  
     Neyts et al. subsequently demonstrated that hydroxyurea potentiated the anti-
herpesvirus activities of purine and pyrimidine nucleoside phosphonate analogs18. We 
show here that RR inhibitors also enhance the antitumor effects of cidofovir in EBV-
transformed epithelial cells and in xenografts of NPC grown in athymic mice.  
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                                     MATERIALS AND METHODS 
Reagents. Cidofovir (HPMPC) was generously provided by Gilead Science. 
Hydroxyurea and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) were purchased from Sigma. Didox (3,4-dihydroxybenzohydroxamic acid) 
was a generous gift from Dr. Howard L. Elford. 
Cells. NPC-KT is an EBV-positive epithelial cell line derived from fusion between 
EBV-negative nasopharyngeal epithelial Ad-AH cells and EBV-positive NPC tissue19. 
Cells were maintained in DMEM supplemented with 10% fetal bovine serum and 
antibiotics. 
MTT Assays. NPC-KT cell proliferation was analyzed by MTT assay17,20. 
Administration of cidofovir, RR inhibitors (hydroxyurea or didox), or combinations 
of drugs was done once at the beginning of culture. Cells were treated with 
phosphate-buffered saline solution (PBS) or drug(s); then the MTT assay was 
performed on days 1, 3, and 5. Each well was rinsed twice with PBS and incubated 
for 5 hours in medium with 20 μl of 5 mg/ml MTT dissolved in PBS. After removal 
of medium from each well, 200 μl of DMSO were added to each well and pipetted 
repeatedly to dissolve crystals. Spectrophotometric absorbance at 595 nm (for 
formazan dye) was measured with absorbance at 655 nm for reference. 
Western Blot Analysis. NPC-KT cells were treated with PBS or drug(s) for 72 hours. 
The cleavage of poly (ADP-ribose) polymerase (PARP) during apoptosis was 
described previously21,22. The cleavage of the protein was analyzed by rabbit 
polyclonal anti-PARP antibody with Western blot analysis as described17. 
NPC Xenografts Grown in Athymic Nude Mice. The NPC xenograft C15 was 
passaged in athymic nude mice as described previously16,17.  
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Intratumoral Treatment. Cidofovir was prepared as a 20 mg/ml solution in PBS that 
was neutralized to pH 7.4 and sterilized through filtration. Hydroxyurea was prepared 
in an 80 mg/ml solution in PBS. Mixed solutions of cidofovir and hydroxyurea were 
also prepared. The NPC xenograft C15 was grown subcutaneously until the size of the 
tumor reached 0.1 cm3. Intratumoral injection with 75 μl of drug(s) or PBS daily for 
21 consecutive days was then carried out (Table I). Tumor size was estimated weekly 
by measuring the dimensions of the tumors with calipers.  
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                                                    RESULTS 
Effects of Cidofovir and RR Inhibitors on NPC-KT cells. We first used the MTT 
assay to detect the effects of cidofovir, hydroxyurea, and didox on the proliferation of 
NPC-KT cells, an EBV-positive epithelial cell line. NPC-KT cells (103) were treated 
with either PBS or drug in each well. The viability of the cells was measured by MTT 
assay at days 1, 3, and 5. The absorbance values indicate the degree of cell viability. 
At 1 mM, cidofovir strongly reduced the viability of NPC-KT cells compared with the 
effects at 0.1 mM (Fig. 1 A). The cytotoxic effect of hydroxyurea on NPC-KT cells 
was maximal at concentrations greater than 0.125 mM (Fig. 1 B). Didox, another RR 
inhibitor, significantly reduced NPC-KT cell-viability at concentrations of 0.1 mM or 
more (Fig. 1C).  
RR Inhibitors enhance Cidofovir-induced Cell Toxicity in NPC-KT cells. 
Cidofovir (1 mM) is cytotoxic for NPC-KT cells in vitro17. The cytotoxic effects of 
RR inhibitors at concentrations greater than 0.125 mM and 0.1 mM of hydroxyurea 
and didox, respectively, were pronounced. We next tested the effects of combinations 
of 0.125 mM and 0.0625 mM of hydroxyurea or 0.1 mM and 0.05 mM  of didox with 
1 mM cidofovir. Combination of 1 mM cidofovir and 0.125 mM hydroxyurea 
exaggerated the cytotoxic effect of each RR inhibitor alone at day 5 (Fig. 2 A). The 
cytotoxic effect of the drug combination appeared to be mainly additive. The 
combination of 1 mM cidofovir and 0.0625 mM hydroxyurea also enhanced the 
cytotoxic effect in an additive fashion, but the effect was more limited (Fig. 2 B). 
Didox also appeared to have some additive effect on the cytotoxic effect of cidofovir 
(Fig. 2 C and D). These results suggest that RR inhibitors enhance the cytotoxic effect 
of cidofovir in NPC-KT cells. 
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Combination of Cidofovir and RR Inhibitors Enhances Apoptosis. Previous 
studies have shown the correlation between PARP cleavage during apoptosis and 
caspase activation22,23. PARP cleavage produces a C-terminal fragment (containing 
the catalytic domain) with 85 kDa and an N-terminal fragment of 24 kDa with the 
DNA-binding domain22. Thus, detection of the 85 kDa product of PARP indicates the 
involvement of caspase-mediated apoptosis. Previously, we showed that treatment of 
NPC-KT cells with 1 mM cidofovir produced a cleaved form of PARP at day 417. 
Here we checked the production of cleaved-PARP at day 3 and could detect faintly 
the 85 kDa cleaved form with 1 mM cidofovir, but more weakly than at day 4 as 
shown previously17 (Fig. 3). NPC-KT cells cultured with 0.125 mM hydroxyurea 
clearly induced cleavage of PARP. Didox (0.1 mM) induced only faintly visible 
cleavage of PARP. Combination of 0.125 mM hydroxyurea or 0.1 mM didox with 
cidofovir produced more pronounced PARP-cleavage than  did 1 mM cidofovir alone. 
These data support the impression that RR inhibitors enhance cidofovir-induced 
cytotoxic effects through caspase-mediated apoptosis.  
Combination of Cidofovir and Hydroxyurea enhances suppression of Growth of 
NPC Xenografts. Intratumoral injections of drug(s) were started when the size of the 
tumor reached 0.1 cm3. Intratumoral injection of cidofovir and hydroxyurea together 
enhanced the growth-inhibitory effect of either drug alone on C15 NPC xenografts 
(Fig. 4). Small changes (average loss ~10%) in body weight were observed in mice 
treated with the combination of cidofovir and hydroxyurea (Table 1). Only the 
combination of cidofovir and hydroxyurea decreased tumor size below the basal level. 
In a single mouse there was complete remission. These results suggest that 
hydroxyurea enhances cidofovir-induced growth inhibition of NPC.  
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                                                     DISCUSSION 
     NPC is an epithelial malignancy with extraordinarily high incidence in southern 
China and in Chinese who migrate elsewhere from this area24. In NPC, EBV infection 
is mainly latent, and the tumors contain episomal viral DNA rather than linear 
genomes. The episome is the basis for latent EBV infection, and its replication is 
accomplished by cellular DNA polymerase, whereas replication of linear genomes in 
the virus-productive state is accomplished by a virally encoded DNA polymerase25. 
NPC C15 is an EBV-positive tumor, which when grown in athymic mice retains 
many of the characteristic features of NPC including histology, cell markers, 
maintenance of a fixed EBV episomal copy number, type 2 EBV latency antigens, 
and lack of viral replication26.    
     Cidofovir (HPMPC) belongs to a new class of antiviral molecules, the acyclic 
nucleoside phosphonate analogs1,2,25. The drug inhibits herpesvirus-encoded DNA 
polymerases27,28. The compound is a potent inhibitor of the cytolytic replication of 
EBV, but does not affect EBV episomal copy number or the growth of latently 
infected lymphocytes25,29. Cidofovir has a uniquely broad spectrum of indications for 
clinical use, encompassing DNA-virus infections, as well as various experimental 
forms of cancer of both viral and non-viral origin including vascular tumors, such as 
hemangiomas and hemangiosarcomas grown in SCID mice30,31,32. For NPC the 
growth inhibition by cidofovir was attributable to induction of apoptosis as shown in 
NPC-KT cells by a DNA-fragmentation assay and by PARP-cleavage17. Here, we 
confirmed that cidofovir has growth-inhibitory effects both in vitro and in vivo. The 
inhibitory effect of cidofovir on tumor growth was consistently through induction of 
apoptosis.  
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     RR plays a central role in DNA biosynthesis furnishing a balance of the 
deoxyribonucleoside triphosphates (dNTPs). The reaction catalyzed in mammalian 
cells represents the rate-limiting step of the de novo synthesis pathway of dNTPs. RR 
can be separated into 2 dissimilar protein components named R1 (large subunit) and 
R2 (small subunit), both necessary for activity11. 
     Here, we show that two RR inhibitors, hydroxyurea or didox, induced apoptosis in 
NPC-KT cells through PARP-cleavage, which indicates that the caspase cascade is 
activated. RR inhibition following exposure to hydroxyurea decreases the size of 
dATP and dGTP pools and increases the dTTP pool-size, resulting in inhibition of 
DNA synthesis33. The clinical use of hydroxyurea as an anticancer agent is based on 
the drug’s ability to block DNA synthesis via inhibition of RR activity. Didox is a 
polyhydroxy-substituted benzohydroxamic acid derivative that belongs to a new class 
of RR inhibitors34. It has been suggested that didox-induced RR inhibition is due to 
the reversible destruction of the R2 tyrosil free radical, as demonstrated for 
hydroxyurea11. However, other results suggest that didox has some other 
properties11,35,36. A hydroxyurea-resistant cell line overexpressing R2 was not cross-
resistant to didox35, and the nucleotide imbalance caused by didox is different from 
that caused by hydroxyurea35,36. Compatible with our results, Grusch et al. showed 
that didox induced apoptosis though caspase 8 or 9 cascades, which resulted in 
cleavage of the caspase substrate PARP in HL60 and K562 leukemia cells37. 
     Abdulkarim et al. showed that cidofovir induced a downregulation of the EBV 
oncoprotein latent membrane protein-1 (LMP1) associated with a decrease of the 
antiapoptotic Bcl-2 and an increase of the proapoptotic Bax protein in NPC C1538. 
Previously, we showed that local or systemic administration of cidofovir produced 
striking effects on growth of LMP1-expressing NPC C15 xenografts. Similar effects 
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were produced in C17 and C18 xenografts which are EBV-positive, but do not 
express detectable LMP1 protein; unlike most primary NPC the latter NPCs have 
mutations in the p53 gene16. Widespread apoptosis was produced in all three types of 
tumors. Thus the data suggest that apoptosis was dependent on neither p53 nor LMP1 
expression in contrast to the results of Abdulkarim et al. 16,38. We had also reported 
previously that PARP-cleavage was induced by cidofovir in NPC-KT cells, which do 
not express LMP117. Although LMP1-signaling might be partially involved, the main 
pathway of cidofovir-induced apoptosis may be LMP1-independent.  
    Chodosh et al. showed that hydroxyurea-treated primary B lymphocytes 
immortalized by EBV ceased to proliferate as episomes were lost, which suggests that 
eradication of EBV with hydroxyurea is an appropriate therapeutic strategy for some 
EBV-associated lymphoid malignancies39. Clinical application of low-dose 
hydroxyurea based on in vitro anti-EBV activity indicates the potential for 
hydroxyurea as a therapeutic agent in EBV-associated lymphoid disease40,41. Huyghe 
et al. demonstrated that the anti-apoptotic protein Bcl-2 and the tumor suppressor p53 
were involved in the development of hydroxyurea-mediated apoptosis in 
lymphoblastoid cell lines. Contrary to our findings, the hydroxyurea-induced cell 
death was limited, and no activation of the caspase cascade was detected in the 
lymphoblastoid cells42. Thus, these observations suggest that induction of apoptosis 
by hydroxyurea should be through a pathway independent of LMP1 and p53 in 
epithelial cells, and that the mechanism of hydroxyurea-induced apoptosis in EBV-
positive epithelial cells is likely to be different than in lymphoblastoid cell lines. The 
mechanism of hydroxyurea-induced apoptosis via the caspase cascade in epithelial 
cells needs to be elucidated.   
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       Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine 
nucleoside and nucleoside phosphate analogs18. The potentiating effect of 
hydroxyurea may stem from depletion of the intracellular dNTP pools, thus favoring 
the triphosphates or diphosphates of the nucleoside analogs in their competition with 
the natural nucleotides at the viral DNA-polymerase level. Cidofovir competes in its 
diphosphate form with native dCTP. Hydroxyurea brings about a decrease in the level 
of the intracellular pools of the different dNTPs. Of all dNTP pools, dATP levels are 
most efficiently depleted by hydroxyurea43. Hydroxyurea (0.05 mM) enhances the 
inhibition of human immunodeficiency virus by PMEA and PMPA both in wild-type 
virus and in clinical isolates resistant to the compounds. These antiviral activities 
should be due to imbalances of dNTP pool sizes44,45. The influence of dNTP 
imbalance on various forms of cancer of both viral and non-viral origin needs more 
investigation. 
     The pronounced effects of the combination of an acyclic nucleoside phosphonate 
analog and a RR inhibitor might be due to cell-cycle arrest in S phase. This 
mechanism accounts for the cell cycle-specificity of hydroxyurea, which produces 
arrest of proliferating cell populations in the G1/S phase of the cell cycle46. Hatse et al. 
examined the effects of PMEA on the cell-cycle distribution pattern in K562 and 
THP-1 cell lines and concluded that cell differentiation and apoptotic cell death are 
two cell-specific alternative responses to PMEA-induced cell-cycle arrest in S phase47. 
Although many pathways could be involved in cidofovir and hydroxyurea-induced 
apoptosis, the mechanism of the additive or synergistic effect of the drugs is unclear. 
Each step in apoptosis will need to be examined to dissect the apoptotic effect of each 
drug on EBV-positive epithelial cells.  
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     Systemic treatment with cidofovir has a nephrotoxic potential in human beings, 
which is lessened when combined with probenecid48. Toxicity of hydroxyurea occurs 
primarily through myelosuppression49. Nude mice treated with a combination of 
cidofovir and hydroxyurea lost ten per cent of their body weight on average in our 
system. It should be possible to devise more effective and less toxic combinations of 
the acyclic nucleoside phosphonate analogs and RR inhibitors that may have potential 
for therapy of patients with NPC, for which effective new agents are needed.    
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                                                   FIGURE LEGENDS 
Fig. 1. Effects of cidofovir and RR inhibitors on NPC-KT cells. NPC-KT cells (103) 
were cultured with (A) cidofovir, (B) hydroxyurea, or (C) didox at indicated 
concentrations, followed by measurement of absorbance at day 1, 3, and 5 in MTT 
assays. Absorbance with SD is shown. 
 
Fig. 2. RR inhibitors enhance cidofovir-induced cell toxicity in NPC-KT cells. The 
effects of combination of cidofovir and hydroxyurea or didox on NPC-KT cell 
viability were evaluated with MTT assays. Absorbance with SD is shown. The effect 
of cidofovir was evaluated at 1 mM and hydroxyurea at (A) 0.125 mM or (B) 0.0625 
mM. Concentrations of didox were (C) 0.1 mM or (D) 0.05 mM. 
 
Fig. 3. Combination of cidofovir and RR inhibitors enhances apoptosis. NPC-KT cells 
were cultured at indicated conditions; then cells were collected at day 3. Protein 
extracts (100 μg) were analyzed for PARP expression by Western blot analysis. 
Bands at 116 kDa and 85 kDa show uncleaved and cleaved forms of PARP, 
respectively. Arrow indicates PARP cleaved by 1 mM cidofovir. 
 
Fig. 4. Combination of cidofovir and hydroxyurea enhances suppression of growth of 
NPC xenografts. NPC C15 growing in athymic nude mice were treated with cidofovir, 
hydroxyurea, or the two drugs combined. Changes in tumor volume in animals 
injected intratumorally daily with 75 μl of a 2% cidofovir solution, 80 mg/ml 
hydroxyurea, the combination, or PBS. Treatment started when the tumors had 
reached a size of 0.1 cm3 and continued for 21 days. Tumor volumes were estimated 
weekly by measuring the dimensions of the tumors with calipers. Relative volumes 
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with SDs are shown for each condition. Significance of “cidofovir alone versus 
cidofovir + hydroxyurea”  (p=0.0063) and “hydroxyurea alone versus cidofovir + 






     
 
 
Table 1 Relative body weight changes after intratumoral injections with 75 μl of drug(s) or PBS daily 
for 21 consecutive days 
 a PBS, phosphate-buffered saline solution. 
Treatment No. of mice treated Relative body weight changes after treatment (SD) 
cidofovir (HPMPC) 9 1.029 (0.020)
hydroxyurea 10 0.989 (0.106)
cidofovir + hydroxyurea 13 0.901 (0.032)
PBS 12 1.021 (0.123)
 a SD, standard deviation. 













































































































































































































































































                                  
 













































































































































































































































                                                              
 
  
 
 
 
